While use of the standard therapy leading to the best outcome against locally advanced rectal cancer has increased over the past decade, only half of patients currently receive it, new research indicates.
While use of the standard therapy leading to the best outcome against locally advanced rectal cancer has increased over the past decade, only half of patients currently receive it, new research indicates.